FDA looks at snoring/apnoea devices:
This article was originally published in Clinica
The US FDA has scheduled a meeting of its Ear Nose and Throat Devices advisory panel and its Dental Products advisory panel to discuss general issues surrounding the prescription use versus the over-the-counter use of devices intended to treat snoring or mild to severe obstructive sleep apnoea. The discussion will include the role of the medical/dental provider in the diagnosis, treatment and follow-up of snoring and OSA; the ability of the patient to self diagnose and treat OSA; the types of clinical data that would be needed to support an over the counter indication and the components of adequate device labelling. The panels will not discuss continuous positive airway pressure devices and surgical treatments for sleep apnea. The meeting will take place on October 6 in Gaithersburg, Maryland
You may also be interested in...
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.
Rosa DeLauro prevails over fellow Democrats Debbie Wasserman Schultz and Marcy Kaptur for Appropriations chair. Frank Pallone gets unanimous support from Democrats to continue as Energy and Commerce chair.